These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9137961)
1. Clinical experience with fludarabine in hemato-oncology. Keating MJ; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S83-91. PubMed ID: 9137961 [TBL] [Abstract][Full Text] [Related]
2. [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine]. Vásová I; Penka M; Hájek R; Mayer J; Krahulcová E Vnitr Lek; 1997 Jan; 43(1):45-50. PubMed ID: 9221567 [TBL] [Abstract][Full Text] [Related]
3. Leukemia: A model for drug development. Keating MJ Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2598-604. PubMed ID: 9815664 [TBL] [Abstract][Full Text] [Related]
4. Role of fludarabine in hematological malignancies. Montillo M; Ricci F; Tedeschi A Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450 [TBL] [Abstract][Full Text] [Related]
5. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052 [TBL] [Abstract][Full Text] [Related]
6. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Lenz G; Hiddemann W; Dreyling M Cancer; 2004 Sep; 101(5):883-93. PubMed ID: 15329894 [TBL] [Abstract][Full Text] [Related]
7. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Keating MJ; McLaughlin P; Plunkett W; Robertson LE; O'Brien S; Gandhi V; Gregoire V; Yang L; Cabanillas F Ann Oncol; 1994; 5 Suppl 2():79-83. PubMed ID: 8204523 [TBL] [Abstract][Full Text] [Related]
8. The expanding role of fludarabine in hematologic malignancies. Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Li YY; Gandhi V Leuk Lymphoma; 1994; 14 Suppl 2():11-6. PubMed ID: 7533576 [TBL] [Abstract][Full Text] [Related]
16. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970 [TBL] [Abstract][Full Text] [Related]
17. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia. Lam CC; Ma ES; Kwong YL Am J Hematol; 2005 Aug; 79(4):288-90. PubMed ID: 16044456 [TBL] [Abstract][Full Text] [Related]
18. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. Shields DJ; Byrd JC; Abbondanzo SL; Lichy JH; Diehl LF; Aguilera NI Mod Pathol; 1997 Nov; 10(11):1151-9. PubMed ID: 9388067 [TBL] [Abstract][Full Text] [Related]
19. Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. O'Brien S; Kantarjian H; Keating MJ Ann Oncol; 1996; 7 Suppl 6():S27-33. PubMed ID: 9010576 [TBL] [Abstract][Full Text] [Related]
20. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]